Nephrotic syndrome after switching from irinotecan, S-1, and bevacizumab combination to trifluridine/tipiracil.

IF 0.7 Q4 UROLOGY & NEPHROLOGY

CEN Case Reports Pub Date : 2025-07-10 DOI:10.1007/s13730-025-01014-0

Jun Takami, Yuta Nakano, Eriko Harada, Shota Nakakuma, Ryosuke Kawamoto, Eisaku Ito, Kayoko Matsukawa

引用次数: 0

Abstract

Trifluridine/tipiracil (FTD/TPI) has shown efficacy in treating advanced colorectal and gastric cancers. Although renal injury due to FTD/TPI is rare, its renal effects have not been well documented. We present the case of a 74-year-old man with metastatic colon cancer who developed nephrotic syndrome with hematuria after transitioning from a regimen of irinotecan, S-1, and bevacizumab to FTD/TPI. Renal biopsy revealed IgA nephropathy with glomerular microangiopathy (GMA). His condition improved with steroid therapy. To our knowledge, this is the first documented case of nephrotic syndrome associated with FTD/TPI. Renal toxicity should be monitored through urinalysis during FTD/TPI treatment.

查看原文本刊更多论文

从伊立替康、S-1和贝伐单抗组合转换为trifluridine/tipiracil后肾病综合征。

Trifluridine/tipiracil （FTD/TPI）已显示出治疗晚期结直肠癌和胃癌的疗效。虽然FTD/TPI引起的肾脏损伤很少见，但其对肾脏的影响尚未得到很好的记录。我们报告了一例74岁的转移性结肠癌患者，在从伊立替康、S-1和贝伐单抗方案过渡到FTD/TPI方案后，出现了肾病综合征并伴有血尿。肾活检显示IgA肾病伴肾小球微血管病变（GMA）。他的病情在类固醇治疗后有所改善。据我们所知，这是第一例与FTD/TPI相关的肾病综合征。在FTD/TPI治疗期间应通过尿液监测肾毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CEN Case Reports UROLOGY & NEPHROLOGY-

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Clinical and Experimental Nephrology (CEN) Case Reports is a peer-reviewed online-only journal, officially published biannually by the Japanese Society of Nephrology (JSN). The journal publishes original case reports in nephrology and related areas. The purpose of CEN Case Reports is to provide clinicians and researchers with a forum in which to disseminate their personal experience to a wide readership and to review interesting cases encountered by colleagues all over the world, from whom contributions are welcomed.